Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
- Status
- Enrolling by invitationResults none
- Why it is watched
- non-weight indication: aging
- Who it enrolls
- age 46 Years to 60 Years; female; excludes diabetes; BMI ≥30 required; conditions: Obesity; Menopause
- Interventions
- semaglutide or tirzepatide; Lifestyle modification intervention
- Conditions
- Obesity; Menopause
- Phase and size
- Phase 4 · 30 participants
- Dates
- Start 2025-05-01
Primary completion 2026-12-31 - Sponsor
- Mayo Clinic (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Physical Function Measure: Short Physical Performance Battery (SPPB) score.24 weeks
- Physical Function Measure: Modified Clinical Test of Sensory Interaction in Balance (mCTSIB) performed on the Rehabilitation Artificial Physical Intelligence Database (RAPID) foot pressure mat24 weeks
- Physical Function Measure: Standing Chest Throw Test with a 2-kg Weighted Ball using Motion Sensor Technology (MST)24 weeks
- Physical Function Measure: Chair-to-Stand Tests using Motion Sensor Technology (MST)24 weeks
- Physical Function Measure: Six-Minute Walk Test (6MWT)24 weeks
- Physical Function Measure: Hand Grip Strength using a Hydraulic Hand Dynamometer24 weeks
- Physical Function Measure: Short Form-12 (SF-12) Health Survey24 weeks
- Physical Function Measure: Patient-Reported Outcomes Measurement Information System (PROMIS) - Fatigue and Physical Function Domains24 weeks
- Aging Biomarkers: Cellular Senescence Markers in Plasma24 weeks
- Difference between biological and chronological age24 weeks
- Vascular Function Assessment: Reactive Hyperemia Index (RHI) using EndoPAT24 weeks
02Eligibility
Who can take part
Inclusion Criteria: * Postmenopausal women (with menopause defined as the cessation of menstrual periods for at least 12 months or history of bilateral oophorecomy) * Age 46-60 years old * BMI ≥ 30 kg/m2. Exclusion Criteria: * Past or current use of menopausal hormone therapy * Early or premature menopause * History of chemically induced menopause * Impaired renal function (GFR ≤29) * Thyroid-stimulating hormone ≥7 with low free T4 * Diabetes * Cardiovascular disease * Elevated blood pressure (\>170/\>95) * Uncontrolled co-morbidities including inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignant, or psychiatric disease * \>5% change in weight during the 3 months prior to screening * Other anti-obesity medication use within the past 3 months * History of bariatric surgery * History of malignant neoplasms within the past 5 years prior to screening * Current use of supplements known to affect weight * Personal or family history of medullary thyroid cancer. * Wheelchair bound * Vision loss
03Change log
Registry changes
No changes recorded since the trial was added.